-
Signature
-
/s/ Lindsey Rolfe
-
Stock symbol
-
CLVS
-
Transactions as of
-
Dec 1, 2021
-
Transactions value $
-
-$1,038
-
Form type
-
4
-
Date filed
-
12/3/2021, 03:16 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
CLVS |
Common Stock |
Options Exercise |
|
+687 |
+0.83% |
|
83K |
Dec 1, 2021 |
Direct |
F1 |
transaction |
CLVS |
Common Stock |
Sale |
-$1.04K |
-346 |
-0.42% |
$3.00* |
82.6K |
Dec 2, 2021 |
Direct |
F2, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
CLVS |
Restricted Stock Units |
Options Exercise |
$0 |
-687 |
-49.96% |
$0.00 |
688 |
Dec 1, 2021 |
Common Stock |
687 |
|
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance